-
1 Comment
Guiyang Xintian Pharmaceutical Co.,Ltd is currently in a long term uptrend where the price is trading 4.1% above its 200 day moving average.
From a valuation standpoint, the stock is 72.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.7.
Guiyang Xintian Pharmaceutical Co.,Ltd's total revenue rose by 6.5% to $239M since the same quarter in the previous year.
Its net income has increased by 3.7% to $36M since the same quarter in the previous year.
Finally, its free cash flow grew by 151.1% to $28M since the same quarter in the previous year.
Based on the above factors, Guiyang Xintian Pharmaceutical Co.,Ltd gets an overall score of 5/5.
| Industry | Biotechnology |
|---|---|
| Sector | Healthcare |
| ISIN | CNE100002QB5 |
| CurrencyCode | CNY |
| Exchange | SHE |
| Dividend Yield | 0.6% |
|---|---|
| Market Cap | 3B |
| Target Price | None |
| PE Ratio | 30.33 |
| Beta | -0.17 |
Guiyang Xintian Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of Chinese medicines for various diseases in China. The company offers formulation products, which include hard capsules, gels, mixtures, granules, and tablets. Its products are used for the treatment of antitumor, gynecological, urinary, breast thyroid, blood, heat, oral, anti-cold, and cardiovascular diseases. The company was founded in 1995 and is based in Guiyang, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 002873.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
